Navigation Links
Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
Date:3/5/2009

n Board or in the "pink sheets." These alternative markets, however, are generally considered to be less efficient than the Nasdaq Capital Market. Many over-the-counter stocks trade less frequently and in smaller volumes than securities traded on the Nasdaq markets, which would likely have a material adverse effect on the liquidity and value of the Company's common stock.

The Company expects to announce its year-end 2008 earnings later this month, following completion of its audit. The Company anticipates it will report approximately $1.4 million of stockholders' deficiency, approximately $15.5 million of cash, cash equivalents and short-term investment securities, and approximately $5.2 million of accounts payable, accrued expenses, accrued compensation and related liabilities. In addition, the Company expects to report approximately $7.2 million of long-term investments in auction rate securities reported at fair value. The Company anticipates that its net loss for the fourth quarter and year ended December 31, 2008, will be approximately $4 million and $53 million, respectively. The Company expects its cash burn to be approximately $3 million per quarter during 2009.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tu
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Genome Sciences at the University of Maryland School of ... Medical Research Institute of Infectious Diseases and Northern Arizona ... their investigation into the anthrax attacks of 2001. The ... microbiology in a criminal investigation. More than 20 people ...
... package designed to minimize the potential risks of synthetic ... available to the gene synthesis industry and synthetic biology ... licensed GenoTHREAT, a software tool that helps detect the ... an open-source project by a team led by Jean ...
... new drug that will regenerate a critical enzyme in ... exposed to deadly chemical warfare agents. Christopher Hadad, ... (OSU), is leveraging Ohio Supercomputer Center (OSC) resources to ... called organophosphorus (OP) nerve agents. "This project ...
Cached Biology Technology:University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 3University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 4Open-source software designed to minimize synthetic biology risks 2OSU chemist developing solution to nerve agent exposure 2
(Date:4/21/2014)... daily pill to lower cholesterol can reduce heart attack ... inflammation could help save the vision of diabetics, scientists ... with high doses of niacin to decrease bad cholesterol ... an effective mark for these patients, said Dr. Pamela ... Georgia Regents University. , Martin is Principal Investigator ...
(Date:4/21/2014)... In recent years, there are growing studies ... for sustained-release and controlled-release of nerve growth ... by Prof. Gao Li and team from ... and Technology in China, amino-functionalized ethylenediamine-treated multi-walled ... nanotubes-nerve growth factor complexes by non-covalent grafting. ...
(Date:4/20/2014)... to treat lung, breast and pancreatic cancers also promote ... University of California, San Diego School of Medicine have ... surface of drug-resistant tumors that appears responsible for inducing ... cancer cells. , The findings, published in the ... Biology , may point to new therapeutic opportunities for ...
Breaking Biology News(10 mins):Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3Cancer stem cells linked to drug resistance 2
... Jewish Health have discovered a type of cell that may ... lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently ... make autoantibodies, which bind to and attack the body,s own ... of the journal Blood , that they found higher ...
... programmed cell death - a process by which cells ... in termites. And it appears this regression may be ... defensive organs, according to Kouhei Toga and Kiyoto Maekawa ... the University of Tokyo, in Japan. Their findings have ...
... tropics make it tough for farmers to keep their crops ... seems to defy efforts to control its population. Some farmers ... the weevils but they have not been successful. Since the ... the immature stages. The sweetpotato weevil is a year round ...
Cached Biology News:B-cell discovery suggests why women suffer more autoimmune disease 2Cells die so defensive organs can live 2Biocontrol of sweetpotato weevils 2
...
... Antibody Modification Services ,,GenScript ... antibody labeling and antibody fragmentation. Labeling ... signals for visualization and quantitation of ... it is preferable to use only ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: